Compare prices and buy DSIP from 40 research peptide vendors - also called suppliers or sources. Updated daily.
Delta sleep-inducing peptide, a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, CAS 62568-57-4) isolated from rabbits and named for the slow-wave sleep activity it induced. No receptor for it has been identified, and its proposed role as a natural sleep factor remains poorly documented. It has been tested in small clinical studies of insomnia and opiate withdrawal and is not FDA-approved.
For research purposes only. Not medical advice.
DSIP is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its name is a description of the assay that found it rather than of anything it is known to do: Schoenenberger and Monnier isolated it from the cerebral venous blood of rabbits during electrically induced slow-wave sleep and characterized it in a 1977 report in the Proceedings of the National Academy of Sciences.
Nearly fifty years later, no receptor for it has been identified. That single fact organizes everything else about the compound. The mechanisms attributed to it (in rats, an opioid-dependent effect on sleep without opioid receptor binding, and a role in sleep-related growth hormone release) are hypotheses drawn from downstream observations rather than from a characterized binding target. DSIP is reported to cross the blood-brain barrier, and its measured plasma half-life is on the order of minutes.
The human record is thin and old. Small clinical studies, most of them European and from the 1980s, examined DSIP in chronic insomnia and in opiate and alcohol withdrawal. Results were inconsistent, and FDA's 2026 review found no form of emideltide registered as a drug in any country it searched. As of October 2026 ClinicalTrials.gov lists no registered study of it.
No FDA-approved drug contains emideltide, and Drugs@FDA lists no application for it.
DSIP is the exception in this group. Of the seven peptides heard at the July 2026 Pharmacy Compounding Advisory Committee meeting, it is the only one the committee voted against.
FDA's review staff had recommended against all seven substances on the agenda. On six of them the committee overrode that recommendation, but on DSIP it agreed with it. FDA cited a lack of safety and effectiveness data for the uses it evaluated, incomplete physical and chemical characterization, and the existence of FDA-approved treatments for insomnia, narcolepsy and opioid withdrawal.
Two consequences are easy to get wrong. First, the no vote did not reverse the April removal: DSIP is no longer in Category 2, and it is not on the bulks list either, so it currently sits in neither bucket. That is a regulatory gap, not a permission. Second, a negative PCAC vote is as non-binding as a positive one. The FDA is not obliged to follow it, and as of October 2026 the bulks-list regulation, 21 CFR 216.23, names emideltide in neither its permitted nor its excluded list. Our writeup of the July 2026 PCAC vote covers the other six substances and what the recommendations do and do not change. Material sold by peptide vendors is offered for laboratory research use only and not for human consumption.
DSIP is sold almost entirely under its initials or the expanded "Delta Sleep-Inducing Peptide."
PeptideScouter indexes DSIP vials per milligram and verifies identity against its molecular formula (C35H48N10O15, CAS 62568-57-4).
No. DSIP is the one substance of the seven heard in July 2026 that the committee voted against. On July 24, 2026 the Pharmacy Compounding Advisory Committee voted 6-7, with one abstention, against recommending it for the 503A bulk drug substances list, a rejection by a single vote. FDA had evaluated it for opioid withdrawal, chronic insomnia and narcolepsy, and its review staff had recommended against adding it, citing insufficient safety and effectiveness data and the existence of FDA-approved treatments for those conditions. The committee agreed.
Emideltide is DSIP's International Nonproprietary Name, the standardized generic name assigned for regulatory use. FDA used it in the July 2026 advisory committee meeting materials. Peptide vendors almost universally use DSIP or delta sleep-inducing peptide instead, which is why coverage of the vote and the products on sale can look like they are describing different substances. They are the same compound, CAS 62568-57-4.
It is not established. DSIP was isolated in the 1970s from the blood of rabbits in induced slow-wave sleep and named for that assay, but no receptor for it has been identified in the roughly fifty years since. Proposed mechanisms (in rats, an opioid-dependent effect on sleep without opioid receptor binding, and a role in sleep-related growth hormone release) are inferences from downstream observations rather than a characterized target. Small clinical studies, most of them European and from the 1980s, in chronic insomnia and in opiate and alcohol withdrawal produced inconsistent results, and FDA's 2026 review found it registered as a drug in no country it searched.
Not by itself. The negative vote did not reverse the earlier removal from Category 2, so DSIP is currently neither on the FDA's Category 2 list nor on the 503A bulks list, which is a gap rather than a permission. A PCAC vote is advisory in both directions, so the FDA is not obliged to act on the rejection any more than on the six recommendations, and nothing about the vote changes the status of research-grade material sold by peptide vendors, which is offered for laboratory use only and not for human consumption.
DSIP is sold by 40 research peptide vendors indexed on PeptideScouter, with 74 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
37 of the 40 indexed vendors currently have DSIP in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
ZC Labs currently lists DSIP at $2.15/mg, the lowest listed price across 40 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.77/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 40 vendors listing DSIP publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $1.97/mg listed to $1.77/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
DSIP ranges from $1.97/mg to $14.00/mg across 74 listings from 40 research peptide vendors, normalized to USD per milligram and refreshed daily.
40 research peptide vendors currently list DSIP on PeptideScouter, with 37 in stock right now. We track 74 listings across size and kit variants.
DSIP's CAS Registry Number is 62568-57-4. It is also sold as Delta Sleep-Inducing Peptide, Delta Sleep-Inducing Peptide (DSIP).
